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811-5 High Success Rate in Recanaiization of Chronic Total 
Coronary Occlusions with a Novel Guidewire Principle 
Using the Guidance of Micro Channels 
812-2 is Doppler Ultrasound Accurate in Screening for 
Restenosis After Carotid Artery Stentlng? A 
Comparison With Quantitative Carotid Angtography 
Heinz, Christian Mueller, Jens Petersen, Helmut Roskamm. Herz-Zenfrum 
Bad Krolingen, Bad Krczfngen, Germany. 
Background: Vascular micro channels (MC) in chronic total coronary occlusions (CTO) 
may guide recanalization wires and improve success rates. The new ACS Cross-ITCXT 
guidewire family has distal tip tapering from 0.014” to 0.010” that eases entrance into 
MC. Tip stiffness increases gradually from the lOOXT-wire to the 400XTwire. 
Methods: We included 204 consecutive pts. with 214 CTO. Age of occlusion was >3 
months to 20 years and occlusion length 24.1(5-60)mm. MC as visible on cineangiogra- 
phy were none in 37% (MC 0), incomplete in 26% (MC 1) complete in 14% (MC 2) and 
complete with distal capillary refill in 23% (MC 3). In all lesions the first attempt was done 
with the 100XTwire trying carefully to stay within MC. If necessary tip stiffness was step- 
wise increased to the 409XTwire. 
Sara Lessio, David J. Clark, Robed Schainfeld. Margaret E. D’Donoghue. William Irwin. 
Jeffrey M. Isner, Kenneth Rosenfield, Sf Elizabeth’s Medical Center of Boston, Bosfcn, 
Massachusetts. 
Results: Success rates for crossing the occlusion were 61% for the lCklXT-wire. 76% for 
all Cross-ITGXT wires and 62% including other additional wire types. Wire success was 
dependent on visibility and completeness of MC (Figure 1). If MC were visible 60% to 
61% of occlusions could be passed with the 1OOXTwire. Vessel success rate was 79%. 
In-hospital events were pericardial tamponada in 0.5%. non-q wave myocardial infarction 
in 1%; no pt. died. 
Conclusions: The use of a new guidewire family with a tapered tip and the concept of 
stepwise increase of wire tip stiffness is safe and very effective in recanalizations of CTO. 
Wire success was significantly dependent on the visibility of MC. 
Background: Limited information exists regarding the accuracy of doppler ultra sound in 
predicting restencsis after carotid artery stenting (CAS). 
Methods: 41 patients underwent both doppler ultrasound and quantitative carotid angicg- 
raphy @CA) at a median of 6 months after CAS in a single center. Ultrasound was per- 
formed by one experienced operator blinded to the results of QCA. Internal carotid 
arteries (ICA) with a peak in stent systolic doppler velocity of >130 crnlsec or a peak dias- 
tolic velocity of >40 cm/set were were classified as having z-60% restenosis. Off line 
QCA was performed by a single investigator blinded to results of the ultrasound. The 
maximum % in stent restencsis of the ICA was calculated using the distal non tapered 
portion of the ICA as a reference. 
Results: 6 of the 41 ICA stems had in stent restenosis of > 60% by QCA. Only 1 ICA res- 
tencsis was symptomatic but all 6 ICA underwent repeat percutaneous carotid intewen- 
tion. Doppler ultrasound had a sensitivity of 33%, specificity of 63%, positive predictive 
value of 13%, and a negative predictive value of 65% in detecting an in stent ICA rest- 
encsis of >60% compared to QCA. The peak in stent ICA doppler velocity correlated 
mild-moderately with the maximum % in stent restenosis by QCA. (r=O.39, p=O.ol 
Conclusion: Peak doppler systolic and diastcllc velocities resulted in several false posl- 
tives and negatives in screening patients for restencsis after carotid artery stenting. 
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812-I Carotid Artery Stenting in Patients at High Clinical Risk 
of CEA Complications: immediate and Long-Term 
Outcome 
Moshiri Shahram. mLiistro, Fabio Sgura, Goran Stankcvic. Alaide Chieffo, 
Davide Maccagni, Carlo Di Mario, Takum Takagi, Antonio Colombo, San Raffaele 
Hospital, Milan, Italy. Cenfro Cuore Columbus, Milan, ffafy 
Background: Carotid endoarterectomy (CEA) has been established as the standard 
treatment for carotid occlusive disease and has been shown to be beneficial in patients 
with high-grade carotid stenosis. Nevertheless this approach is not free of complications. 
Among these, perioperative stroke and death have been reported in 2.5~7.5% but the 
incidence can be as high as 16% in the high risk-patients. The management of penoper- 
ative neurological deficits complicating CEA is still controversial. We have previously 
reported our experience with emergency carotid stenting in small number of patients. 
The aim of this registry is the results of emergency carotid stenting in a larger population. 
Methods and Results: From April 1996 to July 2001, 25 patients underwent emergency 
carotid angioplasty and stenting for perioperatlve stroke. Among all procedures, 21 were 
performed in the hemcdynamic laboratory and the remaining 4 in the operating theatre. 
Carotid angiography was performed immediately (within 15 * 5 min) after the appear- 
ance of neurological symptoms. Thrombosis at the CEA site was found in16 (72%) 
lesions and vessel dissection in the remaining 7 lesions (26%). Adjunctive carotid artery 
angioplasty with direct stent implantation was performed in all patients (within 35 f 12 
min) with a technical success rate of 100%. 3 (12%) deaths occurred in hospital. all 
related to neurological events (within 15 days). At a mean follow-up of 14 i 9 months 
(rang 1 to 26) 1 (4%) death occurred after 3 months, non neurologic-related. One patient 
(4%) had incomplete recovery. Complete neurological status recovery was observed in 
21 patients (64%). 
Conclusions: Emergency percutaneous transluminal angioplasty carotid stenting 
(PTACS) is feasible, safe and effective in the treatment of peri-operative stroke after CEA 
leading to a complete neurological recovery in the majority of the patients. 
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812-3 Carotid Artery Stent Implantation With Cerebral ’ 
Protection: A Multicenter Experience of 320 Procedures 
Bernhard, Fausto Castricta. Nicola Corvaja. Raffaella Manetti, Carlo Cerneni. 
Carlo Di Mario. Pietm Pas&to. Albert0 Cremonesi, Antonio Colombc, Cardic/ogy 
Department, Mirano, ffafg Columbus Clinic, M&no, ffafx 
Background: Distal embolization of debris during percutaneous carotid artery stenting 
may result in neurological deficit. Newly available devices for cerebral protection pcten- 
tially reduce the risk of embolization. 
Methods and Results: 320 consecutive procedures (306 patients) of elective carotid stent 
implantation with cerebral protection performed in 3 different centers were included in a 
prospective registry. 
Cerebral protection was performed using filter devices (60.6% of procedures), occlusive 
distal balloons (17.2%) and endoluminal clamping of the common and external carotid 
artery (2.2%). 
All lesions presented a >70% diameter stencses (mean 62+6%). Mean age of the 
patients was 67all years, 63% ware males, and 56.7% of patients had a previous stroke 
or transient ischemic attack. In 313 procedures (97.6%) it was possible to position a prc- 
teotion device. In 9 of 55 procedures using distal balloon protection this was not tolerated 
by the patient (2.6%). In 317 procedures (99.1%) a stent was successfully placed. Neurc- 
logical complications during the procedure, in-hospital and during 30 days of follow-up 
occurred in 6 patients (1.9%). These were 1 major stroke (0.3%) 3 minor strokes (0.9%) 
and 2 transient ischemic attacks (0.6%). Protection device related complications.all with- 
out neurological symptoms. cccurred in 5 procedures (1.6%). These were 3 distal dissec- 
tions covered with additional stents. 1 diseecion leading to ooclusion of the internal 
carotid artery, and 1 filter entrapment requiring surgical removal. Major adverse cardiac 
events during the 30 days of follow-up occurred in 2 patients (0.6%). 
Conclusions: Routine use of cerebral protection during carotid artery stenting appears 
feasible and safe. In the present registry the incidence of neurological complications was 
low. 
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812-4 Carotid Artery Stenting With Neuroprotection: A Single 
Center Experience 
8,&&.&t, Gary S. Roubin, Jiri J. Vitek. Nadim Al-Mubarak, Rajesh M. Dave, 
Christina Brennan. Sara Mgaieth, Gishel New, Lencx Hill Heart and Vascular Institute, 
NY. New York, Cardiovascular Research Foundation, NY, New York. 
Background: To prevent/reduce the incidence of cerebral embolic events during carotid 
artery stenting, various protection devices are being evaluated. The feasibility, safety and 
efficacy of these systems are currently under investigation. 
Methods: Between 2/2000 - 7/2001, we performed carotid artery stenting using a variety 
of distal protection devices [Percusurge Guard&em (n=133), MednovaTM (n=61), Accu- 
netTM (n=3). AngioguardM (n=4)] in 195 symptomatic and asymptomatic patients (201 
arteries). The decision to use a filter or a balloon occlusion device was based on the ccl- 
lateral circulation and the carotid anatomy cephalad to the stenosis. All patients were 
evaluated by a neurologist at baseline and within 24 hours of the procedure. 
Results: The mean age was 72 + 6 yrs: 24% of the patients were L 60 yrs. 66% were 
asymptomatic: 5% had prior carotid endarterectcmy and 5% had a ocntralateral ccclu- 
sion. Procedural success was 99.0%. There were 5 (2.4%) minor stmkes, no major 
strokes. In the GuardwireTM group, 2 patients had retinal emboli leading to permanent 
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visual loss (1%) and 1 patient (0.5%) had hyperperiusion syndrome. The 2 (2%) non- 
stroke related deaths were from cardio-pulmonary events; the sole (0.5%) neurological 
death was due to intracranial hemorrhage. 
Minor Stroke 5 (2.4%) 
Major Stroke 
Neurological Death 
Non-Stroke Related Death 
Retinal Embolus 
Hyperpedusion Syndrome 
All Strokes and Deaths 
All Embolic Related Events 
0 
1 (0.5%) 
2 (1%) 
2 (1%) 
1 (0.5%) 
6 (4%) 
7 (3.4%) 
Conclusion: 1) Carotid stenting using neumprotection devices is feasible. 2) The proce- 
dural related embolic comolications was 3.4% (minor strokes + retinal emboli) 3) There 
were no major strokes and 1 fatal intracranial hemorrhage. 
812-5 Angiographic and Pathologic Studies of Late Vascular 
Responses to Successful Carotid Artery Stenting 
wOdashiro, Hiroyoshi Yokoi, Katsumi Inoue, Takeshi Kimura, Hideyuki Nosaka, 
Masakiyo Nobuyoshi, Kokura Memorial Hospital, Kitakyushu, Japan. 
Background: There was linle angiographic follow-up data and pathologic studies for 
patients receiving stents at extracranial carotid arteries. The purpose of this study was to 
assess the long-ferm efficacy of carotid artery stenting (CAS) angiographically and histo- 
pathologically. 
Methods: Out of 29 patients with 36 lesions undergoing 6 months follow-up angiogrephy, 
1-2 years follow-up angiography was available in 14 patients with 19 lesions. Quantita- 
tive angiographic analysis was pedoned. Minimal luminal diameter(MLD), interpolated 
referense diameter and % diameter stenosis were measured. Stent sites were divided 
into 10 segments. At each segments, minimal diameter and mean diameter were mea- 
sured. Histopathologic examination was performed in patients undergoing antemortem 
GAS. Temporal Ganges in histologic pattern between 6 months and 3 years were exam- 
ined. 
Results: At stenotic segments greater than 50% before CAS, neointimal hyperplasia 
became greater than other segments at 6 months. Follow-up angiography of 19 lesions 
at 6 months and 1-2 years revealed a decrease in MLD from 4.41&0.55mm immediately 
after stent implantation to 3.45i0.39 mm at 6 months, but no further decrease in diams- 
tar after 6 months. Late improvement in tuminal diameter was observed after 6 months. 
(3.45*0.39mm at 6 months and 3.76eO.3 mm at l-2 years : P=O.O15). Micrographs of the 
stented segment of the 6 months after CAS revealed significant proliferation of smooth 
muscle cells(SMCs) and abundunt deposition of extracellular matrix substance chiefly 
composed of proteoglycans on the intimal side. In contrast, aftre 3 years. neointima was 
primarily composed of dense fibrous collagenous tissue and atrophic SMCs. Lipid core in 
the atheroma was covered with stable neolntima. 
Conclusion: Angiographic outcomes up to 2 years after CAS were favorable. Late 
improvement of neointimal hyperplasia appears to occur after 6 months. Temporal 
changes in histologic panem provide a pathologic backgound for the long-term efficacy 
of CAS. 
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1102-l Previous Cytomegalovirus Infection and the Risk of 
Restenosis After a Strategy of Provisional Stenting 
vMueller. John M. Hodgson, Heinz J. Buenner, Stephan Marsh. Helmut 
Aoskamm, Hen-Zentrum, Bad Kro.?ingen. Gemrany, University Hospital, Base/, 
Switzerland. 
Background: Previous studies have shown that prior infection with cytomegalovirus 
(CMV) is a predictor of restenosis after atherectomy. 
Methods: We prospectively studied 76 consecutive patients scheduled for 6-months fol- 
low-up coronary angiography as par? of the SIPS study. Anti-CMV IgG and IgM antibod- 
ies were measured to determine whether previous exposure to CMV increased the risk of 
restenosis after a strategy of provisional stenting. In 76 patients (99%), the coronary 
angiograms before, directly after and B-months after the intervention could be analyzed 
quantitatively. 
Results: Anti-CMV IgG positive and anti-CMV IgG negative patients had similar minimal 
lumen diameter (MLD) in the target vessel before and directly after the intervention. After 
six months, however, the MLD was significantly smaller in CM&positive as compared to 
CMV-negative patients (1.57eO.62 mm versus 2.00i0.63 mm. ~~0.03). Net lumen gain at 
6 months was significantly lower in CMV-positive patients (0.69*0.79 mm versus 
1.30t0.67 mm, p<O.O4), and the rate of clinically significant restenosis was significantly 
higher (31% versus 7%, p<O.O2). In a mu/tivariate logistic regression model, CMV-serop- 
ositivity was an independent predictor of restenosis (odds ratio 5.7 (95%CI 1.2-30.3, 
p=0.04)). 
Conclusion: CMV-seropositivity is an independent predictor of restenosis following core- 
nary intervention. 
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1102-2 Role of Chlamydia Pneumoniae for Restenosls After 
Percutaneous Coronary Intervention: The SWICA 
(Swiss Cardiovascular Center Chlamydia) Trial 
mMaier. Marco Corti, Thomas Orsucci, Stephan Windecker, Bernhard Meiet, Otto 
M. Hess, Cardiology, University Hospital Zurich, Zurich, Switzerland, Cafdio/og~ Swiss 
Cardiovascular Center Bern, Bern, Switzerland. 
Background: Recently, a reduction of restenosis rate after stenting has been reported in 
patients with high Chlamydia pneumoniae titers treated with the macrolide antibiotic 
roxithromycin. The purpose of the present study (SWICA Trial) was to evaluate the effect 
of clarithromycin for prevention of coronary restenosis in patients with routine percutans- 
ous coronary intervention (PTCA with and without stenting) and concomitant assessment 
of antibody titers. 
Methods and Results: In a randomized, double-blind, placebo-controlled single center 
pilot study 66 patients with coronary artsly disease undergoing PTCA were randomized 
to receive either standard therapy (placebo group, n=42) or treatment with 2x250 mg 
clarithromycin for six weeks (treatment group, n=44). Primary endpoint was angiographic 
restenosis and secondary endpoint major adverse cardiac evsnts (MACE). The patients 
underwent follow-up angiography after 3 months. Stent implantation was performed in 
67% of all cases. Antibody tiers were taken at randomization and at the end of the fol- 
low-up period. Age, gender, body mass index, history of myocardial infarction as well as 
cardiovascular risk factors were evenly distributed in the two groups. Diameter stenosis 
was similar at follow-up (33% vs. 34%, ns) in both groups. Restenosis rate (=-504/o diame- 
ter stenosis) was 23% in the treatment and 21% (ns) in the placebo group, respectively. 
MACE occurred in 16% and 29% (ns). respectively. Antibody titers for Chlamydia pneu- 
moniae, Cytomegalovirus and Helicobacter pylori were similar in the two groups at ran- 
domization and at follow-up without any correlation to restenosis rate. Only Helicobactsr 
pylori titers decreased significantly after antibiotic therapy. 
Conclusions: Restenosis rate after PTCA is not influenced by clarithromycin treatment. 
Ssropositivity for Chlamydia pneumoniae, Cytomegalovirus and Helicobacter pylori was 
not associated with an increased risk of restenosis after percutaneous coronary interven- 
tions. Thus, a major pathogenic role of Chlamydia pneumoniae for restenosis after per- 
cutaneous coronary intervention appears unlikely. 
1102-21 Preprocedural Levels of Acute Phase Reactants Predict 
an Aggressive Clinical Pattern of Restenosis Following 
Coronary Angioplasty 
mBuffon, Giovanna Liuzzo, Marco Centola, Laura Canale, Patrizio Pasqualeni, 
Antonio G. Rebuzzi, Luigi M. Biasucci, Catholic Universify. Rome, /ta/x A.Fa.R., 
Ospedale Fetebenefratelli-/so/a Tiberina, Rome, /ta/y 
Background: In a subset of patients undergoing coronaty angioplasty (PTCA), resteno- 
sis is not a benign clinical event but it is associated with recurrence of severe unstable 
angina (UA), myocardial infarction (Ml) or cardiac death (CD). Acute phase reactants are 
powerful predictors of angiographic restenosis following PTCA, but it is unclear whether 
they can also identify patients with acute coronary events at long term follow-up. 
Methods: We investigated whether pm-procedural plasma levels of C-reactive protein 
(CRP) and serum amyloid-A protein (SAA) might predict the clinical severity of restenosis 
at one year follow-up in a group of 111 consecutive patients undergoing successful sin- 
gle-lesion PTCA. 
Results: At f year, clinical restenosis, defined as recurrence of symptoms and/or posi- 
tive exercise test and confirmed by the angiographic evidence of > 50% stenosis at the 
site of PTCA, occurred in 51 patients (46%). Among them, 26 patients (25%) had a more 
aggressive panern of testenosis requiring urgent hospital admission because of severe 
UA (23 patients, 21%) or MI (5 patients, 5%). Recurrence of VA or Ml was 46% and 50% 
in patients with elevated levels of CRP (> 3 mg/L) and SAA (> 5 mg/L), and 2% 
(P-zO.001) and 6% (PcO.001) respectively in patients with normal levels. Among several 
clinical, angiographic and procedural variables analyzed by Cox proportional hazards 
regression model, CRP was the most powerful independent predictor of an aggressive 
pattern of restenosis (RR=14.3, CI=l.6-111.7, P=O.Oll). 
Conclusions: Our data demonstrate that elevated pm-procedural levels of acute phase 
reactants predict a more aggressive clinical pattern of restenosis, requiring emergeni 
hospitalization. Close post-PICA surveillance is necessary in these patients. 
